PERIODICUM BIOLOGORUM VOL. 114, No 3, 331–336, 2012

UDC 57:61 CODEN PDBIAD ISSN 0031-5362



Management of acute ischemic stroke. The faster, the better

SABINE HÖRER ROMAN HABERL

Department of Neurology and Neurological Intensive Medicine, Klinikum Harlaching, Städtisches Klinikum Muenchen GmbH, Munich, Germany

Correspondence:

Roman Haberl, MD, PhD Department of Neurology and Neurologic Intensive Medicine Klinikum Harlaching, Staedtisches Klinikum München GmbH, Sanatoriumsplatz 2, D-81545 München, Germany E-mail: roman.haberl@klinikum-muenchen.de

Abbreviations:

Abbieviations.						
AF –	atrial fibrillation					
CT –	computed tomography					
DVT –	deep venous thrombosis					
ED –	emergency department					
ER –	emergency room					
mRS –	modified Rankin Scale					
NIHSS -	National Institutes of Health Stroke					
Scale						
NNT –	number needed to treat					
PE –	pulmonary embolism					
rt-PA –	recombinant tissue plasminogen					
activator						
SICH –	symptomatic intracranial					
hemorrha	age					
TIA –	transient ischemic attack					

Received June 18, 2012.

Abstract

Ischemic stroke is an emergency. Immediate ambulance transportation, cautious lowering of excessive blood pressures >220/120mmHg and abstention from heparin and aspirin are the most important measures in the preclinical setting. Hospital prenotification and clearly structured in-hospital pathways can help to reduce delay to treatment. Stroke patients are best treated in dedicated stroke units where vital parameters are monitored and stroke-related complications are recognized. Blood glucose should be in a normal range. Intravenous thrombolysis in the 3 hours window is the only approved efficacious, but time-dependent reperfusion therapy of acute ischemic stroke. Treatment with alteplase >3 to 4.5 hours from symptom onset and in elderly patients >80 years is beneficial and recommended by the European Stroke Organisation, but off-label. In severe stroke with CT-angiographical occlusion of a large intracranial artery, mechanical recanalisation is increasingly used. Only a small proportion of otherwise eligible stroke patients receive reperfusion therapy, mostly due to prehospital delay. The following article highlights on emergency management of acute ischemic stroke, and on strategies how the number of patients who benefit from acute stroke treatment and thrombolytic therapy may be increased.

INTRODUCTION

Time is brain« is the slogan of acute ischemic stroke care, meaning that the earlier stroke treatment starts the better the outcome. Key of the concept is to minimalize the delay from symptom onset to therapy. Handling stroke as an emergency, comparable to acute coronary syndrome, is therefore most important in the preclinical and emergency room setting. Intravenous thrombolysis with alteplase within 3 hours is the only approved specific treatment of acute ischemic stroke. The benefit of thrombolytic therapy is time dependent (1, 2). For every 10 minutes delay within 1-3 hours after stroke onset, 1 fewer patient out of 100 has a favourable outcome after systemic thrombolysis (2).

In reality, the majority of ischemic stroke patients do not receive thrombolysis because they do not reach the hospital soon enough (3, 4). For them, general acute stroke treatment including respiratory and cardiac care, fluid and metabolic management, blood pressure, glycaemic and temperature control, and treatment of stroke-related neurologic complications within the first hours to days after stroke is particularly important (5). This article is focussed on the emergency management of acute ischemic stroke, and on strategies how delay to treatment may be reduced. As a result, more patients would have access to acute stroke care, stroke units, and recanalization therapies.

Prehospital stroke management

Initialization of the emergency chain is the crucial first step for successful stroke treatment. However, time from symptom onset to alarming of emergency facilities accounts for the largest proportion of delay time in management of acute ischemic stroke (6). Among the general population, there is discrepancy between good theoretical knowledge about stroke symptoms and taking action in the emergency situation (7, 8): Frequently, family members rather than the patients themselves contact emergency services (8). Informational campaigns distributed by mass media including TV, internet, social networks, and newspapers, must therefore encourage everybody to make an emergency call immediately, once stroke symptoms are suspected. Under the headline »Recognize & Respond«, for example, the »Power to end stroke« project of the American Stroke Association offers an internet based teaching of stroke signs followed by the instruction to call 911 (www.powertoendstroke.org).

Aside from raising public awareness towards stroke, training of emergency dispatchers, paramedics and emergency room staff improves preclinical stroke management. During emergency phone calls, stroke is often described as »collapse«, »fall«, »stroke« or »speech problems« (9). Structured interviews with standardised questions can clarify the condition. Patients with facial droop, prior stroke or TIA (7) and severe clinical deficit (10) are most probable to receive a correct preclinical diagnosis of stroke, indicating that more subtle stroke symptoms may sometimes be misinterpreted or overseen. The Face-Arm--Speech Test (FAST) (11, 12) is a simple instrument that helps to identify stroke or TIA on scene or in the ER and assists further triage of patients.

Primary care doctors may also be involved in preclinical stroke management and should be encouraged that every suspected stroke needs urgent evaluation and emergency hospital admission (13). Transportation by ambulance ensures faster arrival compared to private vehicles (10,14). Whenever possible, transportation should be to the nearest hospital with a stroke unit. Prenotification of ED and stroke unit physicians during transport reduces in-hospital delay (15, 16) and leads to increased use of thrombolysis (16, 17).

For transportation, patients should receive an intravenaus access and 0.9% saline by the ambulance staff. Aspirin and heparin are contraindicated before intracranial hemorrhage is excluded by CT scan. Hypertension should be tolerated up to 220/120 mmHg. Oxygen should be supplied if oxygen saturation falls below 95% (18).

In-hospital management

Emergency room

Presentation to the emergency department via ambulance is in general the fastest way of referral for stroke patients (10, 14, 19). In some cases (rural area, distance to hospital > 45 miles/72 km), helicopter transportation might be preferred (20).

Immediate ER triage, neurological evaluation including NIHSS, general physical examination, laboratory tests, and a native CT scan (CT angiogram when large vessel occlusion is suspected) are needed (18). Stroke and TIA mimics to be ruled out include epileptic seizures, syncopes, sepsis (21), migraine with aura (22), and hypoglycemia. Although not a part of routine implementation (23), clearly structured in-hospital pathways can contribute to rapid evaluation and decision making in acute stroke. For example, by simultaneous alarming of all involved hospital staff, door to imaging time was significantly shortened in a recent single-center study (24). After completion of diagnostic exams, stroke patients should be transported to the stroke unit, without delay.

Stroke Unit

Irrespective of age, gender, stroke subtype and severity, stroke unit care significantly reduces death, dependency and the need for institutional care in stroke survivors when compared to stroke patients treated in conventional wards (25). Stroke units are dedicated wards with specialized multidisciplinary staff focussed on treatment of acute stroke and recognition of stroke related complications. Stroke teams consist of doctors, nurses, physiotherapists, occupational therapists, speech and language therapists and social workers (26) who collaborate in a coordinated way to do patient care. Personnel and technical equipment of a stroke unit should allow close assessment of the neurological status, monitoring of vital parameters within 72 hours after severe stroke, and provide early mobilization and sometimes rehabilitation (18).

General stroke management

Whereas stroke is acutely life-treatening in the minority of cases, many patients need stabilization of vital functions during the first hours to days after ischemic stroke. Treatment strategies aim at normalizing respiratory and cardiac functions, glucose, blood pressure, and fluid balance, and at preventing stroke-related complications (5, 18).

Cardiac monitoring

Stroke patients are at increased risk of cardiac arrhythmias, especially AF, myocardial infarction, heart failure and sudden death (27, 28). Troponin levels are often slightly elevated during acute stroke, even in the absence of acute coronary syndrome, and thought to be due to stroke-related sympathoadrenal activation (29). Therefore every stroke patient should have an ECG on admission. Further cardiac monitoring serves to maintain normal heart rates and can reveal paroxysmal AF as a common cause of stroke (18). AF may also be detected by frequent pulse controls through trained nurses during the first 72 hours on the stroke unit, which is an evolving new concept due to the low sensitivity of Holter ECG at later time points.

Blood glucose

Hyperglycemia occurs frequently (30–40%; up to 60% in non-diabetics) in acute stroke and is associated with poor outcome and death, especially in patients without known diabetes (30, 31). Hyperglycemia was shown to be associated with hemorrhagic transformation of stroke (32) and larger infarct volumes (33, 34). However, it is uncertain if correction of elevated glucose levels improves clinical outcomes. To date, correction of glucose levels above 180 mg/dL (10 mmol/L) with insulin, and below 50mg/dl (2.8mmol/L) with 10–20% glucose or dextrose bolus is recommended (18).

Blood pressure

As hyperglycemia, hypertension is common in acute ischemic stroke, and associated with increased risk of poor outcome (35). Due to impaired cerebral autoregulation during acute stroke, every change in systemic blood pressure directly affects cerebral blood flow. Hypertension may result in hemorrhagic transformation of the infarcted area, whereas hypotension may cause further damage to the penumbra. Despite such pathophysiological considerations, the optimal blood pressure management in acute ischemic stroke is not known. It is also unclear whether early discontinuation from preexisting antihypertensive treatment (about 50% of patients) is necessary (36). Beneficial effects of early hypertension control (37) could not be reproduced (38). In the absence of conclusive data, current guidelines recommend moderate lowering of raised blood pressure over 220/120 mmHg, and over 185 mmHg systolic in thrombolysed patients using intravenous labetolol or urapidil (18), approximately by 15-25% during the first 24 hours after stroke (39). Sublingual nifedipine has been described to cause abrupt decrease in blood pressure (40), and is therefore not a drug of first choice. In clinical practice, after permissive hypertension during the first 24 hours within the mentioned limits for nonthrombolysed and thrombolysed patients, antihypertensive medication may be continued or started from day 2.

Evidence how to handle hypotension is even more scarce. Low blood pressure at stroke onset is unusual (41), and is recommended to be raised with saline 0.9% or volume expanders when associated with neurological deterioration. Inotropic support is only needed in patients with hypotension due to low cardiac output (18).

Oxygen, fluid, and fever

Oxygen should be supplied (usually 2–4 L/min via nasal tube) if saturation is below 95%. Saline 0.9% is recommended for fluid replacement during the first 24 hours after stroke. Fluid balance and electrolytes should be further monitored in dysphagic patients with severe deficit or impaired consciousness. Pyrexia (body temperature >37.5°C) should be treated with paracetamol and prompt the search for infections (18).

Infections

Bacterial pneumonia due to aspiration is one of the most frequent complications of acute ischemic stroke (42) and should be treated with antibiotics. Aspiration occurs in patients with dysphagia or impaired consciousness and may be prevented by feeding by nasogastric tube, pulmonary physical therapy, and early mobilization (18). Prophylactic antibiotic treatment, in contrast, may be harmful (43).

As pneumonia, urinary tract infections commonly occur in hospitalized patients, mostly due to indwelling catheters (44). Roughly half the stroke patients expose incontinence at stroke onset (45), so that urinary catheterization is at least temporarily needed. Antibiotics should be used once urinary tract infection is diagnosed. Bladder catheters should be removed as soon as possible. However, 25% and 15% of patients will be incontinent at discharge and one year after stroke, respectively (45).

Deep venous thrombosis

Immobilization due to paresis is a risk factor for deep venous thrombosis (DVT) and consecutive pulmonary embolism (PE). Early mobilization, rehydration and subcutaneous low molecular weight heparin can reduce the risk of DVT and PE in stroke patients without increasing the risk of hemorrhage (18, 46).

Falls

Many stroke symptoms – hemiparesis, ataxia, vertigo, visual field defect, lower limb hypaesthesia, cognitive impairment, and depression – as well as polypharmacy lead to impaired gait balance and expose patients to increased risk of injury and falls. Hypovitaminosis D can be seen within one week after hemiplegic stroke (47). Falls occur in up to 25% of acute stroke patients, leading to serious injury, including hip fractures, in up to 5% (48). Physical exercise (49), mobilization, and supplementation of vitamin D (50), calcium, and biphosphonates (50, 51) can reduce fracture rates among acute stroke patients and should be provided in the acute setting. Drugs leading to postural instability, e.g. neuroleptics, should be avoided whenever possible.

Agitation and delirium

Confusion, agitation and delirium are common problems in the acute phase of stroke. A search for underlying treatable causes often reveals dehydration, electrolyte dysbalance, fever, substance withdrawal, or nonconculsive epileptic seizures. When sedation or neuroleptics cannot be avoided, choice of drugs should take into account potential side effects. Sedation can lead to impaired consciousness and thus increase the risk of aspiration and falls, so substances with short half-time periods, such as lorazepame, may be preferred. Antipsychotics, among them risperidone (52), have been associated with increased risk of cerebrovascular accidents in the elderly (53), risk of myocardial infarction in demented patients on cholinesterase inhibitors (54), and death (52). The risk of cerebrovascular accidents seems to be greatest within the first weeks of drug intake (55), making the use of typical and atypical antipsychotics in the acute stroke setting even more hazardous. General recommendations are lacking, and prescription will be an individual decision based on comorbitidy and estimated harm if psychotic symptoms are left untreated. For example, a delirant stroke patient with Parkinson's disease might be treated with quetiapine rather than risperidone or typical antipsychotics, whereas a demented stroke patient with aggression may benefit from low-dose risperidone or olanzapine.

Recanalization therapies

Intravenous thrombolysis

Systemic thrombolysis with rt-PA within 3 hours is the only approved evidence-based therapy of acute ischemic stroke (56, 57). Beyond 3 to 4.5 hours, intravenous thrombolysis remains effective and safe (1), but is yet unapproved by European medical authorities. Cerebral hemorrhage has to be excluded by CT scan before thrombolysis is started. As an off-label procedure, intravenous thrombolysis in the extended time window is routinely performed in experienced stroke centers. Data from the multicentre SITS-ISTR stroke registry showed that in 2009 there was a substantial increase (from 7% to 22%) in thrombolysis within 3 to 4.5 hours compared to 2008 (58). However, the benefit of thrombolysis remains time--dependent (NNT in terms of a favourable outcome = 7within 3 hours, 14 by 3 to 4.5 hours) (1). Overall, the risk of SICH and mortality are slightly higher in patients thrombolysed within the extended time window, but the proportion of patients with favourable clinical outcome after 90 days is similar (58, 59).

Thrombolysis >80 years of age

About 30% of strokes occur in people >80 years of age (60, 61). Whereas approval criteria restrict thrombolysis to younger patients, it is now clear that older age is not a reason to preclude someone from treatment: Risk and benefit must be weighted. Elderly stroke patients have higher bleeding rates. Mortality is also higher, but so is pre-stroke comorbidity. However, functional outcome in terms of mRS is significantly better in patients >80 years after thrombolysis vs. without, and similar to younger patients (62, 63).

Mechanical recanalization

In recent years, an increasing number of mechanical recanalization devices have been used to treat severe strokes with intracranial large artery occlusion as shown by CT angiography. The rates of good outcome (mRS = 0-2) in creased to 45 % with the latest techniques (Table 1) – rather acceptable for patients having very severe strokes (64–67). For selection of patients the mismatch of cerebral blood flow and cerebral blood volume on contrast enhanced CT is used more and more instead of the time window (Figure 1). Perfusion CT has the advantage of being fast, widely available and less affected by artefacts than diffusion weighted and perfusion weighted magnetic resonance imaging.

Mobile Stroke Unit

Maximal benefit from thrombolysis would be obtained if started immediately after symptom onset. A new approach to minimize the delay-to-treatment-decision is the concept of mobile stroke units. These are high-tech ambulance cars equipped with a CT scanner, teleradiological connection, and laboratory. The aim is to start in-




Figure 1. Contrast enhanced perfusion CT allows to differentiate regions with reduced cerebral blood flow (A) and normal cerebral blood volume (B). This mismatch permits mechanical recanalization efforts.

	NINDS rt-PA	SITS-MOST	PROACT II	Multi-MERCI	Penumbra Pivotal	Solitaire (Pilot)		
Number of patients	312	6483	121	164	125	20		
NIHSS	18	12	17	19	18	19		
Recanalization (%)	-	_	66	57	82	90		
90 d-mRS 0-2 (%)	28	54	40	36	25	45		

 TABLE 1

 Mechanical recanalization devices in comparison to the results of NINDS and SITS-MOST

travenous thrombolysis during transportation, once eligibility criteria have been checked. Two pilot projects are currently ongoing in Germany. One of them reports a dramatic reduction in alarm-to-needle times (time from emergency call to beginning of thrombolysis) when patients are transported by, and treated in the mobile stroke unit (68).

CONCLUSION

Every minute counts in the treatment of acute ischemic stroke. Raised stroke awareness within the population, rapid diagnosis by paramedics and primary care doctors, transportation by ambulance cars, hospital prenotification and well organized in-hospital pathways contribute to early beginning of stroke therapy. The extended time window for systemic thrombolysis and recent data supporting thrombolysis in elderly patients >80 years of age offer the possibility that more patients receive this specific therapy for acute ischemic stroke. Acute general stroke management is best done at a multiprofessional stroke unit for 48–72 hours and deals with stroke-related metabolic, cardiorespiratory, inflammatory, and neuropsychiatric problems.

REFERENCES

- HACKE W et al. 2008 Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (13): 1317–29
- LANSBERG M G, BLUHMKI E, THIJS V N 2009 Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. *Stroke* 40 (7): 2438–41
- DEREX L et al. 2002 Factors influencing early admission in a French stroke unit. Stroke 33(1): 153–9
- BARBER P A et al. 2001 Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. *Neurology 56(8)*: 1015–20
- LEYS D *et al.* 2007 The main components of stroke unit care: results of a European expert survey. *Cerebrovasc Dis* 23(5–6): 344–52
- **6.** EVENSON K R *et al.* 2009 A comprehensive review of prehospital and in-hospital delay times in acute stroke care. *Int J Stroke* 4(3): 187–99
- MOSLEY I et al. 2007 Stroke symptoms and the decision to call for an ambulance. Stroke 38(2): 361–6
- **8.** RITTER M A *et al.* 2007 Discrepancy between theoretical knowledge and real action in acute stroke: self-assessment as an important predictor of time to admission. *Neurol Res* 29(5): 476–9
- **9.** THE ESCORTT GROUP 2012 *The identification of acute stroke: an analysis of emergency calls. Int J Stroke:* (E pub ahead of print)
- MAESTRONI A *et al.* 2008 Factors influencing delay in presentation for acute stroke in an emergency department in Milan, Italy. *Emerg Med J* 25(6): 340–5
- NOR A M et al. 2004 Agreement between ambulance paramedicand physician-recorded neurological signs with Face Arm Speech Test (FAST) in acute stroke patients. Stroke 35(6): 1355–9

- HARBISON J et al. 2003 Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 34(1): 71–6
- ROEBERS S et al. 2007 Attitudes and current practice of primary care physicians in acute stroke management. Stroke 38(4): 1298–303
- DEBIAIS S et al. 2007 [Creation of a regional stroke network in Tours hospital (France): consequences for stroke care and thrombolysis]. Rev Neurol (Paris) 163(8–9): 817–22
- BELVIS R *et al.* 2005 Benefits of a prehospital stroke code system. Feasibility and efficacy in the first year of clinical practice in Barcelona, Spain. *Cerebrovasc Dis*, 19(2): 96–101
- LINDSBERG P J et al. 2006 Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology 67(2): 334–6
- DOUGLAS V C *et al.* 2005 Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke? *Neurology* 64(3): 422–7
- 2008 Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. *Cerebrovasc Dis* 25(5): 457–507
- MOSLEY I et al. 2007 The impact of ambulance practice on acute stroke care. Stroke 38(10): 2765–70
- THOMAS S H et al. 2002 Nontrauma helicopter emergency medical services transport: annotated review of selected outcomes-related literature. Prehosp Emerg Care 6(2): 242–55
- NOR A M *et al.* 2005 The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrument. *Lancet Neurol.* 4(11): 727–34
- HORER S G, SCHULTE-ALTEDORNEBURG, HABERL R L 2011 Management of patients with transient ischemic attack is safe in an outpatient clinic based on rapid diagnosis and risk stratification. *Cerebrovasc Dis* 32(5): 504–10
- KWAN J, SANDERCOCK P 2003 In-hospital care pathways for stroke: a Cochrane systematic review. *Stroke* 34(2): 587–8
- NOLTE C H et al. 2011 Improvement of Door-to-Imaging Time in Acute Stroke Patients by Implementation of an All-Points Alarm. J Stroke Cerebrovasc Dis (E pub ahead of print)
- Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev (4): pCD000197
- LANGHORNE P, POLLOCK A 2002 What are the components of effective stroke unit care? Age Ageing 31(5): 365–71
- BAMFORD J et al. 1990 The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry 53(10): 824–9
- **28.** BRODERICK J P *et al.* 1992 Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. *Stroke* 23(9): 1250–6
- BARBER M *et al.* 2007 Elevated troponin levels are associated with sympathoadrenal activation in acute ischaemic stroke. *Cerebrovasc Dis* 23(4): 260–6
- CAPES S E *et al.* 2001 Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. *Stroke* 32(10): 2426–32
- ZSUGA J et al. 2012 Different effect of hyperglycemia on stroke outcome in non-diabetic and diabetic patients-a cohort study. Neurol Res 34(1): 72–9
- **32.** PACIARONI M *et al.* 2009 Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. *Cerebrovasc Dis* 28(2): 119–23
- PARSONS M W et al. 2002 Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 52(1): 20–8

- BAIRD T A et al. 2003 Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 34(9): 2208–14
- Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev, 2001(3): p. CD000039.
- ROBINSON T G et al. 2010 Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. *Lancet Neurol* 9(8): 767–75
- POTTER J et al. 2009 Controlling hypertension and hypotension immediately post stroke (CHHIPS)-a randomised controlled trial. *Health Technol Assess* 13(9): iii, ix-xi, 1–73
- 38. SANDSET E C *et al.* 2010 Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). *Int J Stroke* 5(5): 423–7
- JAIN A R, BELLOLIO M F, STEAD L G 2009 Treatment of hypertension in acute ischemic stroke. *Curr Treat Options Neuro* 11(2): 120–5
- 40. GROSSMAN E et al. 1996 Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 276(16): 1328–31
- LEONARDI-BEE J et al. 2002 Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 33(5): 1315–20
- WEIMAR C et al. 2002 Complications following acute ischemic stroke. Eur Neurol 48(3): 133–40
- CHAMORRO A et al. 2005 The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. Stroke 36(7): 1495–500
- GERBERDING J L 2002 Hospital-onset infections: a patient safety issue. Ann Intern Med 137(8): 665–70
- 45. THOMAS L H et al. 2008 Treatment of urinary incontinence after stroke in adults. Cochrane Database Syst Rev (1): CD004462
- 46. DIENER H C et al. 2006 Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke 37(1): 139–44
- **47.** SATO Y *et al.* 2000 Influence of immobilization upon calcium metabolism in the week following hemiplegic stroke. *J Neurol Sci* 175(2): 135–9
- FORSTER A, YOUNG J 1995 Incidence and consequences of falls due to stroke: a systematic inquiry. *BMJ 311(6997)*: 83–6
- 49. ENG J J, PANG M Y, ASHE M C 2008 Balance, falls, and bone health: role of exercise in reducing fracture risk after stroke. J Rehabil Res Dev 45(2): 297–313
- SATO Y et al. 2005 Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. *Cerebrovasc Dis* 20(3): 187–92
- SATO Y et al. 2005 Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165(15): 1743–8

- MAGLIONE M et al. 2011 Off-Label Use of Atypical Antipsychotics: An Update (Internet). Comparative Effective Reviews No. 43. Rockville (MD): Agency for Healthcare Research and Quality (US)
- **53.** WANG S *et al.* 2012 Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. *Stroke* 43(1): 28–31
- PARIENTE A et al. 2012 Antipsychotic use and myocardial infarction in older patients with treated dementia. *Arch Intern Med* 172(8): 648–53
- SACCHETTI E, TURRINA C, VALSECCHI P 2010 Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. *Drug Saf 33(4)*: 273–88
- The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995 Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333(24): 1581–7
- HACKE W et al. 1995 Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13): 1017–25
- AHMED N et al. 2010 Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 9(9): 866–74
- 59. SHOBHA N, BUCHAN A M, HILL M D 2011 Thrombolysis at 3–4.5 hours after acute ischemic stroke onset–evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. *Cerebrovasc Dis* 31(3): 223–8
- 60. BONITA R et al. 1994 Stroke incidence and case fatality in Australasia. A comparison of the Auckland and Perth population-based stroke registers. Stroke 25(3): 552–7
- MARINI C et al. 2004 Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 62(1): 77–81
- 62. FORD G A et al. 2010 Intravenous alteplase for stroke in those older than 80 years old. Stroke 41(11): 2568–74
- 63. MISHRA N K *et al.* 2010 Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. *BMJ* 341: c6046
- 64. ROTH C et al. 2010 Stent-assisted mechanical recanalization for treatment of acute intracerebral artery occlusions. Stroke 41(11): 2559–67
- 85. FURLAN A et al. 1999 Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282(21): 2003–11
- 66. SMITH W S *et al.* 2008 Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke* 39(4): 1205–12
- 67. CLARK W et al. 2009 The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. *Stroke 40(8)*: 2761–8
- 68. WALTER S et al. 2012 Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. *Lancet Neurol* 11(5): 397–404